Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Clinical Impact of Hypophosphatemia
Panelists discuss how the lower incidence of hypophosphatemia and related complications with ferric derisomaltose and ferric isomaltoside compared with ferric carboxymaltose influences treatment selection, monitoring protocols, and preventive strategies for patients requiring intravenous iron therapy.
EP: 1.Background and Causes of Iron Deficiency Anemia
EP: 2.Pathophysiology of Iron Deficiency Anemia
EP: 3.Symptoms and Epidemiology of Iron Deficiency Anemia
EP: 4.Diagnosis and Common Comorbidities Seen With Iron Deficiency Anemia
EP: 5.Monitoring Patients With Iron Deficiency Anemia After Diagnosis
EP: 6.Oral vs IV Iron in Clinical Practice
EP: 7.FDA-Approved IV Iron Formulations
EP: 8.Factoring in Safety Considerations With IV Iron Products
EP: 9.Adverse Effects Associated With Hypophosphatemia
Now Viewing
EP: 10.Clinical Impact of Hypophosphatemia
EP: 11.Clinical and Economic Consequences of Nonadherence to IV Iron
Video content above is prompted by the following:
- Considering the incidence of hypophosphatemia in patients with IDA was significantly lower with the use of FDI and FXT than with FCM therapy, how does this impact the choice of treatment?
- How do you monitor phosphate levels?
- A retrospective analysis found a significantly higher combined event rate of fracture, radiological signs of osteomalacia, and kidney stones among patients treated with FCM than after ferric derisomaltose (FDI) treatment. Do these results impact your clinical decision-making?
- What potential interventions or preventative measures could be taken to mitigate the risk of hypophosphatemia in patients receiving IV iron formulations?
Related Videos
Related Content
Understanding TB Symptoms, Spread, Treatment Amid Kansas City Outbreak
February 13th 2025Article
In part 2 of this interview, Michael A. Bernstein, MD, highlights the need for prolonged antibiotics and strong public health measures to combat tuberculosis (TB) at both the individual and population levels.
Read More
